Unique Presentation of Glioblastoma with Acute Onset Symptomatology and Disease Recurrence
DOI:
https://doi.org/10.63682/jns.v13i1.8841Keywords:
glioblastoma, adverse events, seizureAbstract
Background: The most common and dangerous type of primary brain tumor is glioblastoma. Focused neurological abnormalities are common in the brief clinical histories that patients typically bring to the clinic.
Objective: Aim was to determine the clinical presentation of glioblastoma and it’s postoperatively outcomes.
Methods: This prospective/observational study was conducted at Hayatabad Medical Complex, Peshawar from December 2022 to March 2024. Total 35 patients of both gender were presented after providing informed written consent. The CNS tumor registry was used to gather demographic information as well as data on adverse occurrences. Means and standard deviations were the results of the data analysis. SPSS 23.0 was used to analyze all data.
Results: The included cases had mean age 65.9 years. 22 (62.9%) cases were males and 13 (37.1%) were females. Post-operatively psychiatric/neurological adverse events were observed early as compared to cardiovascular/respiratory and general adverse events. Frequency of seizure was 25 (71.4%) among all cases.
Conclusion: The adverse events that patients with glioblastoma experience are categorized as follows: psychiatric/neurological, cardiovascular/respiratory, and general. At least one seizure will be experienced by the majority of patients.
Downloads
References
The 2021 WHO classification of tumors of the central nervous system: a summary. Louis DN, Perry A, et al. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106
Kapoor M, Gupta V. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2024. Astrocytoma.
Brown NF, Ottaviani D, Tazare J, et al. Cancers (Basel) 2022;14:3161. doi: 10.3390/cancers14133161.
Diagnosis and management of glioblastoma: a comprehensive perspective. Gilard V, Tebani A, Dabaj I, et al. J Pers Med. 2021;11:258. doi: 10.3390/jpm11040258
Genetic architectures and cell-of-origin in glioblastoma. Kim HJ, Park JW, Lee JH. Front Oncol. 2020;10:615400. doi: 10.3389/fonc.2020.615400.
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016—2020. Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. Neuro Oncol. 2023;25:1–99. doi: 10.1093/neuonc/noad149.
Brown T.J., Brennan M.C., Li M., Church E.W., Brandmeir N.J., Rakszawski K.L., Patel A.S., Rizk E.B., Suki D., Sawaya R., et al. Association of the Extent of Resection with Survival in Glioblastoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2016;2:1460–1469. doi: 10.1001/jamaoncol.2016.1373
Oppenlander M.E., Wolf A.B., Snyder L.A., Bina R., Wilson J.R., Coons S.W., Ashby L.S., Brachman D., Nakaji P., Porter R.W., et al. An Extent of Resection Threshold for Recurrent Glioblastoma and Its Risk for Neurological Morbidity. J. Neurosurg. 2014;120:846–853. doi: 10.3171/2013.12.JNS13184.
Montemurro N., Perrini P., Blanco M.O., Vannozzi R. Second Surgery for Recurrent Glioblastoma: A Concise Overview of the Current Literature. Clin. Neurol. Neurosurg. 2016;142:60–64. doi: 10.1016/j.clineuro.2016.01.010
Kazmi F., Soon Y.Y., Leong Y.H., Koh W.Y., Vellayappan B. Re-Irradiation for Recurrent Glioblastoma (GBM): A Systematic Review and Meta-Analysis. J. Neurooncol. 2019;142:79–90. doi: 10.1007/s11060-018-03064-0
A. Omuro, L.M. DiAngelis. Glioblastoma and other malignant gliomas: a clinical review.JAMA., 310 (17) (2013), pp. 1842-1850, 10.1001/jama.2013.280319
A.C. Tan, D.M. Ashley, G.Y. López, M. Malinzak, H.S. Friedman, M. Khasraw. Management of glioblastoma: State of the art and future directionsCA Cancer J Clin., 70 (4) (2020), pp. 299-312, 10.3322/caac.21613
B. Flechl, C. Sax, M. Ackerl, et al.The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiother Oncol., 125 (2) (2017), pp. 228-233, 10.1016/j.radonc.2017.07.027
P.D. Delgado-Lopez, E.M. Corrales-Garcia.Survival in glioblastoma: a review on the impact of treatment modalities Clin Transl Oncol., 18 (2016), pp. 1062-1071, 10.1007/s12094-016-1497
Isaac T, Mansour N. Atypical Presentation of Glioblastoma: A Case Report. Cureus. 2024 Oct 22;16(10):e72160. doi: 10.7759/cureus.72160.
Gutin P.H., Phillips T.L., Wara W.M., Leibel S.A., Hosobuchi Y., Levin V.A., Weaver K.A., Lamb S. Brachytherapy of Recurrent Malignant Brain Tumors with Removable High-Activity Iodine-125 Sources. J. Neurosurg. 1984;60:61–68. doi: 10.3171/jns.1984.60.1.0061.
Chan T.A., Weingart J.D., Parisi M., Hughes M.A., Olivi A., Borzillary S., Alahakone D., Detorie N.A., Wharam M.D., Kleinberg L. Treatment of Recurrent Glioblastoma Multiforme with GliaSite Brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2005;62:1133–1139. doi: 10.1016/j.ijrobp.2004.12.032.
Baehr A., Trog D., Oertel M., Welsch S., Kröger K., Grauer O., Haverkamp U., Eich H.T. Re-Irradiation for Recurrent Glioblastoma Multiforme: A Critical Comparison of Different Concepts. Strahlenther. Onkol. 2020;196:457–464. doi: 10.1007/s00066-020-01585-0.
Tsien C.I., Pugh S.L., Dicker A.P., Raizer J.J., Matuszak M.M., Lallana E.C., Huang J., Algan O., Deb N., Portelance L., et al. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J. Clin. Oncol. 2023;41:1285–1295. doi: 10.1200/JCO.22.00164.
J., Mikkelsen T., Shah M., Ryu S., Siddiqui M.S., Walbert T. Randomized Prospective Trial of Fractionated Stereotactic Radiosurgery with Chemotherapy versus Chemotherapy Alone for Bevacizumab-Resistant High-Grade Glioma. J. Neurooncol. 2020;148:353–361. doi: 10.1007/s11060-020-03526-4.
Chun S.-J., Park S.-H., Park C.-K., Kim J.W., Kim T.M., Choi S.H., Lee S.-T., Kim I.H. Survival Gain with Re-Op/RT for Recurred High-Grade Gliomas Depends upon Risk Groups. Radiother. Oncol. 2018;128:254–259. doi: 10.1016/j.radonc.2018.05.024
Straube C., Elpula G., Gempt J., Gerhardt J., Bette S., Zimmer C., Schmidt-Graf F., Meyer B., Combs S.E. Re-Irradiation after Gross Total Resection of Recurrent Glioblastoma: Spatial Pattern of Recurrence and a Review of the Literature as a Basis for Target Volume Definition. Strahlenther. Onkol. 2017;193:897–909. doi: 10.1007/s00066-017-1161-6
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
